2006年，厦门生物医药孵化器设立，标志着海沧生物医药产业发展开启。
September 2006 The establishment of Xiamen Biopharmaceutical Incubator marked the opening of the Haicang Biopharmaceutical Industry.
2011年，由厦门生物医药港企业——厦门万泰沧海生物技术有限公司研发的国家一类新药、中国第一支重组戊型肝炎疫苗“益可宁”（S20110005）正式获批上市。
December, 2011 The China's first recombinant hepatitis E vaccine "Yike Ning" (S20110005), Class I national new drug, developed by Xiamen Bio Bay Enterprise - Xiamen Innovax Biotech CO., LTD., was officially approved to launch.
2016年，由厦门生物医药港重点企业——厦门特宝生物工程股份有限公司研发的国家生物制品Ⅰ类新药——聚乙二醇干扰素α-2b注射液（治疗慢性病毒性肝炎）“派格宾”（证书编号CN20160064）正式获批上市。
October 2016 Peginterferon alfa-2b injection(treated for chronic viral hepatitis, certificate number CN20160064), Class I National New Drug developed by Xiamen Bio Bay Key Enterprise - Xiamen Amoytop Biotech Co., Ltd. was officially approved to launch.
2016年，厦门生物医药协同创新中心开工建设，项目占地8.79万平方米，建筑面积21.3万平方米，规划25栋办公、研发和生产楼。
December 2016 The Xiamen Biopharmaceutical Collaborative Innovation Center started construction. The project covers an area of 87,900 square meters and a construction area of 213,000 square meters. It plans 25 office, R&D and production buildings
2017年，厦门生物医药港重点诊断试剂企业——厦门艾德生物科技股份有限公司（股票代码300685）在深圳证券交易所挂牌上市；厦门生物医药港重点医疗器械企业——大博医疗科技股份有限公司（股票代码002901）在深圳证券交易所中小板成功挂牌上市。
August 2017 Xiamen Bio-Bay Key Diagnostic Reagent Company - Amoy Diagnostics Co., Ltd. (stock code 300685) was listed on the Shenzhen Stock Exchange;
Xiamen Bio-Bay Key Medical Equipment Company - Double Medical Technology Inc. (stock code 002901)was successfully listed on the Shenzhen Stock Exchange.
